High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients

Pharmacogenetic studies in chronic myelogenous leukemia (CML) typically use a candidate gene approach. In an alternative strategy, we analyzed the impact of single nucleotide polymorphisms (SNPs) in drug transporter genes on the molecular response to imatinib, using a DNA chip containing 857 SNPs co...

Descripción completa

Detalles Bibliográficos
Autores principales: Delord, Marc, Rousselot, Philippe, Cayuela, Jean Michel, Sigaux, François, Guilhot, Joëlle, Preudhomme, Claude, Guilhot, François, Loiseau, Pascale, Raffoux, Emmanuel, Geromin, Daniela, Génin, Emmanuelle, Calvo, Fabien, Bruzzoni-Giovanelli, Heriberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858547/
https://www.ncbi.nlm.nih.gov/pubmed/24123600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858547/
https://www.ncbi.nlm.nih.gov/pubmed/24123600

Ejemplares similares